$EVFM
Evofem Biosciences, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459017022496 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.060M $910.0K
YoY Change -51.82% -48.59%
% of Gross Profit
Research & Development $930.0K $960.0K
YoY Change -86.77% -93.69%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $1.980M $1.870M
YoY Change -78.55% -88.99%
Operating Profit
YoY Change
Interest Expense $10.00K -$490.0K
YoY Change -103.57% 75.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Income Tax
% Of Pretax Income
Net Earnings -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$852.8K -$1.026M
COMMON SHARES
Basic Shares Outstanding 13.83M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.50M $14.40M
YoY Change -69.5% -71.93%
Cash & Equivalents $11.68M $14.36M
Short-Term Investments
Other Short-Term Assets $1.000M $500.0K
YoY Change -50.0% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.50M $14.90M
YoY Change -68.53% -71.51%
LONG-TERM ASSETS
Property, Plant & Equipment $109.3K $100.0K
YoY Change -41.34% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $316.7K $300.0K
YoY Change -18.03% -25.0%
TOTAL ASSETS
Total Short-Term Assets $12.50M $14.90M
Total Long-Term Assets $316.7K $300.0K
Total Assets $12.82M $15.20M
YoY Change -68.05% -71.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $503.7K $800.0K
YoY Change -87.46% -87.5%
Accrued Expenses $398.5K $600.0K
YoY Change -82.68% -83.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $902.2K $1.400M
YoY Change -90.09% -88.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $902.2K $1.400M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $900.0K $1.400M
YoY Change -94.48% -92.96%
SHAREHOLDERS EQUITY
Retained Earnings -$125.9M -$123.9M
YoY Change 11.54% 19.9%
Common Stock $137.8M $137.7M
YoY Change 0.82% 1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$181.1M $13.77M
YoY Change
Total Liabilities & Shareholders Equity $12.82M $15.21M
YoY Change -68.05% -71.13%

Cashflow Statement

Concept 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Depreciation, Depletion And Amortization $20.00K $10.00K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$2.880M -$3.130M
YoY Change -78.78% -73.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -3.990M
YoY Change -100.0% -10075.0%
NET CHANGE
Cash From Operating Activities -2.880M -3.130M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 -3.990M
Net Change In Cash -2.880M -7.120M
YoY Change -78.68% -39.09%
FREE CASH FLOW
Cash From Operating Activities -$2.880M -$3.130M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.880M -$3.130M
YoY Change -78.78% -73.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
93382
CY2016Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000
CY2017Q3 neot Accrued Severance Current
AccruedSeveranceCurrent
191496
CY2016Q4 neot Accrued Severance Current
AccruedSeveranceCurrent
109525
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1382
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
137763499
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125850355
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13365846
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5500
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5500
us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
9514058
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
11914526
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12816718
us-gaap Net Income Loss
NetIncomeLoss
-7633677
us-gaap Net Income Loss
NetIncomeLoss
-11046525
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Depreciation And Amortization
DepreciationAndAmortization
25652
us-gaap Depreciation And Amortization
DepreciationAndAmortization
52896
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-55705
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-962
us-gaap Paid In Kind Interest
PaidInKindInterest
100290
us-gaap Share Based Compensation
ShareBasedCompensation
565410
us-gaap Share Based Compensation
ShareBasedCompensation
970381
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-649541
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1467577
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
494206
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4911427
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5843163
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
485942
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
52400
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3459
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33542
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3459
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-10018858
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5834204
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-23384704
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11677852
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37948603
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5843648
CY2016Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14563899
us-gaap Interest Paid
InterestPaid
664292
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
69420
neot Non Cancelable Operating Lease Agreement Date
NonCancelableOperatingLeaseAgreementDate
2015-01-20
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
130572
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
410848
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
431507
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
109293
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1082220
neot Agreement Of Reorganization And Merger Date
AgreementOfReorganizationAndMergerDate
2017-10-17
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
93382
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14363899
CY2016Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1636830
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1262170
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
100577
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
254049
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
78114
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
144729
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
342374
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
352644
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
90143
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
854581

Files In Submission

Name View Source Status
0001564590-17-022496-index-headers.html Edgar Link pending
0001564590-17-022496-index.html Edgar Link pending
0001564590-17-022496.txt Edgar Link pending
0001564590-17-022496-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
neot-10q_20170930.htm Edgar Link pending
neot-20170930.xml Edgar Link completed
neot-20170930.xsd Edgar Link pending
neot-20170930_cal.xml Edgar Link unprocessable
neot-20170930_def.xml Edgar Link unprocessable
neot-20170930_lab.xml Edgar Link unprocessable
neot-20170930_pre.xml Edgar Link unprocessable
neot-ex311_7.htm Edgar Link pending
neot-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending